Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.
As Biogen Cuts 11% of Staff, Company Doubles Down on Clinical Trials
Alzheimer's, Alzheimer's Diseases, Analysts, Autoimmune Disease, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biotech, Biotechnology, Clinical Trials, Health, Infections, Inflammatory Bowel Disease, Inflammatory Bowel Disease, Job Cuts, Multiple Sclerosis, Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy (PML), Quarterly results, R&D, Sales, Secondary Progressive Multiple Sclerosis (SPMS), Shares, SharesNovember 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s […]
In Face of Dropping Stocks and Failed Phase III, Biogen Restructures, Slashes Programs and Lays off 880 People
Analysts, Biologics, Forecasts, Jobs, Layoffs, Lupus, Market Value, Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy (PML), Progressive Multifocal Leukoencephalopathy (PML), Quarterly results, R&D, Restructuring, Sales, Secondary Progressive Multiple Sclerosis (SPMS), Stocks, StocksCambridge, Mass.-based Biogen, Inc. (BIIB) announced today that it was restructuring, cutting 11 percent of its workforce, and slashing programs. In addition, the company announced that its Phase III ASCEND […]